Clinical trial
A Phase I Trial of Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
NCT07701889 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Trial of Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
- Lead sponsor
- Roswell Park Cancer Institute
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- October 31, 2029
- Enrollment
- 21 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.